Anti-SARS-CoV-2 Nucleocapsid (N) (Clone NP1-B9) - Biotin

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is an enveloped, single-stranded, positive-sense RNA virus belonging to the Coronaviridae family1.

The SARS-CoV-2 genome encodes four essential proteins: the spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins2.

SARS-CoV-2 shares 79.6% identity with the original SARS-CoV2.

The N protein is 46 kDa and consists of two highly conserved structural domains, the N-terminal domain (NTD) and C-terminal domain (CTD), connected by a linker region.

The NTD and CTD are involved in a couple of primary functions, including RNA binding and self-oligomerization3,4.

This results in binding to and packaging of the viral RNA genome into a helical ribonucleoprotein5.

The N protein is involved in other critical steps of the viral life cycle, including transcription, replication, and modulating infected cell signaling pathways6,7.

The N protein is a suitable candidate for vaccine development and diagnostic assays8 for several reasons.

It is abundantly expressed during infection and is highly conserved, sharing 90% amino acid homology with the SARS-CoV N protein9.

Furthermore, antibodies9,10 and memory T cells11,12 targeting the N protein are identified in the sera of convalescent COVID-19 patients, demonstrating it as immunogenic.

The N protein also suppresses antiviral RNAi, evading the innate immune system13, suggesting its potential value as a targeted therapeutic.